The effect of mitoTEMPO on the development of hypoxia‐induced pulmonary hypertension in male mice
Physiological Reports · 2026
DOI: 10.14814/phy2.70804 ↗At a glance
Journal article in Physiological Reports, 2026. Written by Esraa M Zeidan and 12 co-authors. Institution: Excellence Cluster Cardio-Pulmonary Institute (CPI), University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Rese…. Major MEDLINE topics: Hypertension, Pulmonary, Organophosphorus Compounds, Hypoxia, Antioxidants. Cited 2 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft (DFG), Cardio-Pulmonary Institute (CPI), Deutsche Forschungsgemeinschaft (DFG) and NSF (National Science Foundation).
Abstract (original language)
Mitochondrial reactive oxygen species (mtROS) have been implicated in the development of chronic hypoxia‐induced pulmonary hypertension (PH), potentially through hypoxia‐inducible factor‐1α (HIF‐1α) stabilization. However, the role of mtROS in HIF‐1α stabilization, PH development, and the therapeutic potential of antioxidant treatment remains controversial. Mice were exposed to hypoxia (10% O 2 ) for 4 weeks to induce PH and treated with mitochondria‐targeted antioxidant mitoTEMPO or its carrier control, triphenylphosphonium (TPP + ). Cell proliferation was evaluated in mouse pulmonary arterial smooth muscle cells (PASMCs) by BrdU incorporation. HIF‐1α stabilization and downstream target expression were investigated in mouse lung carcinoma epithelial (CMT167) cells and isolated mouse and human PASMCs under different hypoxic conditions. In vivo mitoTEMPO treatment did not affect chronic hypoxia‐induced PH compared to TPP + . In vitro, mitoTEMPO treatment did not inhibit hypoxia‐induced mouse PASMCs proliferation but enhanced proliferation under normoxic conditions. In vitro exposure of CMT167 cells and mouse or human PASMCs to mitoTEMPO or TPP + did not alter HIF‐1α protein levels or expression of its downstream targets lactate dehydrogenase A ( Ldha ) and pyruvate dehydrogenase kinase 1 ( Pdk1 ) under normoxic (21% O 2 ) or hypoxic (1% or 10% O 2 ) conditions after 24 h. These findings do not support a therapeutic benefit of mitoTEMPO in hypoxia‐induced PH.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Excellence Cluster Cardio-Pulmonary Institute (CPI), University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig University, Giessen, Germany.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, South Valley University, Qena, Egypt.
- Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI) Giessen, Giessen, Germany.
ORCID profiles: Natascha Sommer, Claudio Nardiello
Funding
- Deutsche Forschungsgemeinschaft (DFG)
- Cardio-Pulmonary Institute (CPI)
- Deutsche Forschungsgemeinschaft (DFG) and NSF (National Science Foundation)
- National Science Foundation
Cite
APA
Zeidan, E. M., Nagarajan, S. A., Sydykov, A., Bier, J., Brosien, M., Taye, A., Pak, O., Ghofrani, H. A., Schermuly, R. T., Seeger, W., Weissmann, N., Sommer, N., & Nardiello, C. (2026). The effect of mitoTEMPO on the development of hypoxia‐induced pulmonary hypertension in male mice. Physiological Reports. https://doi.org/10.14814/phy2.70804
Vancouver
Zeidan EM, Nagarajan SA, Sydykov A, Bier J, Brosien M, Taye A, et al. The effect of mitoTEMPO on the development of hypoxia‐induced pulmonary hypertension in male mice. Physiological Reports. 2026. doi:10.14814/phy2.70804
BibTeX
@article{Zeidan2026,
author = {Zeidan, Esraa M and Nagarajan, Sai Aparna and Sydykov, Akylbek and Bier, Jens and Brosien, Monika and Taye, Ashraf and Pak, Oleg and Ghofrani, Hossein A and Schermuly, Ralph Theo and Seeger, Werner and Weissmann, Norbert and Sommer, Natascha and Nardiello, Claudio},
title = {The effect of mitoTEMPO on the development of hypoxia‐induced pulmonary hypertension in male mice},
journal = {Physiological Reports},
year = {2026},
doi = {10.14814/phy2.70804}
}
EUVIMED